Ísland - íslenska - LYFJASTOFNUN (Icelandic Medicines Agency)

alvogen ehf. - ropinirolum hýdróklóríð - forðatafla - 2 mg

Ísland - íslenska - LYFJASTOFNUN (Icelandic Medicines Agency)

alvogen ehf. - ropinirolum hýdróklóríð - forðatafla - 4 mg

Ísland - íslenska - LYFJASTOFNUN (Icelandic Medicines Agency)

alvogen ehf. - ropinirolum hýdróklóríð - forðatafla - 8 mg

Evrópusambandið - íslenska - EMA (European Medicines Agency)

orion corporation - rópíníról stutt og long-term - dopaminergic lyf, dópamín örvum - hundar - framkalla uppköst í hunda.

Ísland - íslenska - LYFJASTOFNUN (Icelandic Medicines Agency)

glaxosmithkline pharma a/s - ropinirolum hýdróklóríð - forðatafla - 2 mg

Ísland - íslenska - LYFJASTOFNUN (Icelandic Medicines Agency)

glaxosmithkline pharma a/s - ropinirolum hýdróklóríð - forðatafla - 4 mg

Ísland - íslenska - LYFJASTOFNUN (Icelandic Medicines Agency)

glaxosmithkline pharma a/s - ropinirolum hýdróklóríð - forðatafla - 8 mg

Evrópusambandið - íslenska - EMA (European Medicines Agency)

glaxosmithkline (ireland) limited - niraparib (tosilate monohydrate) - fallopian tube neoplasms; peritoneal neoplasms; ovarian neoplasms - Æxlishemjandi lyf - zejula is indicated: , as monotherapy for the maintenance treatment of adult patients with advanced epithelial (figo stages iii and iv) high-grade ovarian, fallopian tube or primary peritoneal cancer who are in response (complete or partial) following completion of first-line platinum-based chemotherapy. , as monotherapy for the maintenance treatment of adult patients with platinum sensitive relapsed high grade serous epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in response (complete or partial) to platinum based chemotherapy.

Ísland - íslenska - LYFJASTOFNUN (Icelandic Medicines Agency)

alvogen ehf. - ciprofloxacinum hýdróklóríð - filmuhúðuð tafla - 500 mg

Ísland - íslenska - LYFJASTOFNUN (Icelandic Medicines Agency)

alvogen ehf. - ciprofloxacinum hýdróklóríð - filmuhúðuð tafla - 250 mg